Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations
Panelists discuss the factors influencing the choice between isatuximab and daratumumab for induction therapy in transplant-eligible newly diagnosed multiple myeloma, as well as the role of dara-based quadruplet regimens as the standard of care and considerations for triplet regimens in specific patient populations.
Video content above is prompted by the following:
- What is your approach to clinical decision-making between isatuximab and daratumumab approaches in induction for transplant-eligible newly diagnosed multiple myeloma (TE NDMM)? Which specific patient characteristics or clinical scenarios would influence your choice?
- Do you consider dara-based quadruplet induction regimens the standard of care for patients with TE NDMM?
- In which patients would you consider induction with a triplet regimen?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
